Avacta Group Hails Milestone In Multi-Affimer Production

LONDON (Alliance News) - Avacta Group PLC on Tuesday said it has reached a milestone on its platform development after achieving easy and high-yielding production of multi-affimer formats.

Avacta said a range of multi-meric affimer constructs central to the group's immuno-oncology programme have been successfully generated and manufactured with very strong production yields via simple production systems.

Avacta said this is a key milestone as low manufacturing yields are a common problem for biotherapeutic platforms and can lead to significant development delays.

"The ease with which we have been able to produce a wide range of important multi-affimer structures and fusion proteins is a strong validation of the affimer platform and was an important pre-clinical milestone to be achieved," said Chief Executive Alastair Smith.

Avacta shares were up 3.2% to 112.00 pence.

By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance

Copyright 2016 Alliance News Limited. All Rights Reserved.

Avacta Group